Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-313 in Malignant Pleural Effusions
NCT03869697Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilunermin alfa in malignant pleural effusion (MPE), sponsored by Clover Biopharmaceuticals. Primary endpoint: Occurrence of Dose-Limiting Toxicity at 21 days. Started Nov 2019; status: completed.
02
Drugs
rilunermin alfa
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT03869697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869697.